Bringing a Vaccine Out of the Lab and Into cGMP Manufacturing
Streptococcus pneumoniae is a bacteria that can cause life-threatening pneumonia, meningitis, and sepsis, as well as otitis media in children. GPN Vaccines developed a ground-breaking broad-spectrum vaccine against Streptococcus pneumoniae that has the potential to save up to two million lives each year.
However, GPN Vaccines’ most substantial challenge was yet to come. After the company achieved favorable preclinical results, it had to develop a reproducible manufacturing process for the vaccine to be used in clinical trials. Unfortunately, GPN Vaccines didn’t have the manufacturing capacity. That’s when it turned to BioCina. GPN Vaccines chose BioCina for its gold-standard quality, regulatory affairs management, microbial expertise, speed, and manufacturing capacity.